HeartBeam appoints Dr. Michael R. Jaff to board effective July 24, 2023

HeartBeam, Inc.

Board size increased to 8 directors to accommodate appointment of Dr. Jaff.
Dr. Jaff is CMO and VP at Boston Scientific; former Harvard professor and hospital president.
He is founder of VasCore and Past-President of the Society for Vascular Medicine.
No family relationships or related party transactions reported with the new director.
Press release announcing appointment issued on July 26, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael R. Jaff

director

BEAT · HeartBeam, Inc.

Effective: 2023-07-24
Filed: July 26, 2023, 7:59 PM ET

On July 24, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Michael R. Jaff as a director of the Company (the “Appointment”) effective as of July 24, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael R. Jaff was appointed as director at HeartBeam, Inc..

Action: appointed
Role: director

Exact text from the filing

On July 24, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Michael R. Jaff as a director of the Company (the “Appointment”) effective as of July 24, 2023.

View on SEC.gov

HeartBeam, Inc. filing history →

Source: SEC EDGAR

accession 0001779372-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.